Předmět: |
|
Zdroj: |
Gene Therapy Weekly; 6/27/2024, p1859-1859, 1p |
Abstrakt: |
Researchers from Seattle Children's Hospital have developed guidelines for the development of a safety surveillance plan for early-phase clinical trials of gene therapy. The researchers emphasize the importance of identifying and characterizing safety signals early in clinical development to protect trial participants. The guidelines address regulatory requirements and governance for safety signal identification and risk assessment. This research was supported by the NIH National Center for Advancing Translational Sciences. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|